Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Modeling human neurodegeneration with iPSCs: opportunities, limitations, and the challenge of aging
Shijie Wang, Lisa Elia, Weiyi Liu, Steven Finkbeiner
Shijie Wang, Lisa Elia, Weiyi Liu, Steven Finkbeiner
View: Text | PDF
Review

Modeling human neurodegeneration with iPSCs: opportunities, limitations, and the challenge of aging

  • Text
  • PDF
Abstract

Most neurodegenerative diseases reflect patient-specific combinations of polygenic risk variants interacting with aging and environmental factors, rather than a single causative mutation. Phase III clinical trial failure rates for neurodegenerative indications exceed 95%, reflecting in part the limitations of existing preclinical systems to fully model the human genetic context of disease. Patient-derived induced pluripotent stem cells (iPSCs) have the potential to address this shortcoming by faithfully recapitulating human cell biology and preserving each patient’s complete genetic architecture. This Review examines iPSC-based models of neurodegeneration across three themes. First, we discuss mechanisms revealed by these models, from convergent pathways uncovered by familial mutations to early evidence that sporadic disease biology is accessible at sufficient cohort scale. Second, we evaluate culture systems from 2-dimensional monocultures to organoids, examining how increasing complexity expands addressable biological questions while introducing trade-offs. Third, we address the aging problem: reprogramming erases epigenetic signatures of donor aging, removing the cellular context in which late-onset sporadic neurodegeneration emerges. We discuss strategies approximating aging in iPSC-derived neurons and highlight direct conversion strategies that preserve native epigenetic age, enabling access to age-dependent phenotypes. We propose a framework matching model systems to biological questions, improving mechanistic understanding and therapeutic development.

Authors

Shijie Wang, Lisa Elia, Weiyi Liu, Steven Finkbeiner

×

Figure 1

Genetic architecture determines the optimal assay window in iPSC models of neurodegeneration.

Options: View larger image (or click on image) Download as PowerPoint
Genetic architecture determines the optimal assay window in iPSC models ...
The figure contrasts two disease architectures and their implications for assay design in iPSC-based studies. In polygenic (sporadic) neurodegeneration (left), many common variants each exert a small individual effect. Their signals are weak at upstream steps but accumulate at convergent downstream cellular endpoints; thus, assays placed at the convergent level provide the greatest sensitivity for detecting polygenic risk. In monogenic (familial) disease (right), a single high-penetrance variant drives a large primary effect at the molecular level. Homeostatic mechanisms progressively buffer this effect at each downstream step, so the optimal assay window lies closest to the primary molecular event. Environmental exposures (center, yellow) and cellular aging (center, red) modulate both architectures across multiple levels, including epigenetic marks, RNA and protein levels, and signaling pathways, progressively reducing cellular resilience, lowering the threshold at which accumulated damage produces a disease state.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts